Use

This test provides information on 49 genes from a patient’s tumor specimen that may be helpful in guiding cancer treatment. These genes were selected based on actionability of mutations identified in those genes, using currently available evidence from national and international guidelines and literature. The panel includes tumor mutation burden (TMB) and microsatellite instability (MSI), which enable simultaneous assessment of eligibility for immune checkpoint inhibitors. Significant genomic findings are annotated according to AMP reporting guidelines and are reviewed and validated by a Quest pathologist who prepares a clinical report.